Responses
Clinical/translational cancer immunotherapy
Original research
INBRX-120, a CD8α-targeted detuned IL-2 that selectively expands and activates tumoricidal effector cells for safe and durable in vivo responses
Compose a Response to This Article
Other responses
No responses have been published for this article.